146 related articles for article (PubMed ID: 32234541)
1. PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target.
Wang J; Wang L; Chen S; Peng H; Xiao L; E Du ; Liu Y; Lin D; Wang Y; Xu Y; Yang K
Gene; 2020 Jun; 744():144608. PubMed ID: 32234541
[TBL] [Abstract][Full Text] [Related]
2. PKMYT1: A Potential Target for CCNE1 Amplificated Colorectal Tumors.
Fang Y; Zhang X; Guo Y; Dong Y; Liu W; Hu X; Li X; Gao D
Cell Biochem Biophys; 2023 Sep; 81(3):569-576. PubMed ID: 37572218
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase, membrane‑associated tyrosine/threonine 1 is associated with the progression of colorectal cancer.
Jeong D; Kim H; Kim D; Ban S; Oh S; Ji S; Kang D; Lee H; Ahn TS; Kim HJ; Bae SB; Lee MS; Kim CJ; Kwon HY; Baek MJ
Oncol Rep; 2018 Jun; 39(6):2829-2836. PubMed ID: 29658598
[TBL] [Abstract][Full Text] [Related]
4. CCNE1 Amplification and PKMYT1 Inhibition Are Synthetic Lethal.
Cancer Discov; 2022 Jul; 12(7):OF12. PubMed ID: 35522064
[TBL] [Abstract][Full Text] [Related]
5. Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1.
Najjar A; Platzer C; Luft A; Aßmann CA; Elghazawy NH; Erdmann F; Sippl W; Schmidt M
Eur J Med Chem; 2019 Jan; 161():479-492. PubMed ID: 30388464
[TBL] [Abstract][Full Text] [Related]
6. Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II.
Platzer C; Najjar A; Rohe A; Erdmann F; Sippl W; Schmidt M
Bioorg Med Chem; 2018 Aug; 26(14):4014-4024. PubMed ID: 29941193
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
[TBL] [Abstract][Full Text] [Related]
8. Effects of MCRS1 on proliferation, migration, invasion, and epithelial mesenchymal transition of gastric cancer cells by interacting with Pkmyt1 protein kinase.
Wang XM; Li QY; Ren LL; Liu YM; Wang TS; Mu TC; Fu S; Liu C; Xiao JY
Cell Signal; 2019 Jul; 59():171-181. PubMed ID: 30953699
[TBL] [Abstract][Full Text] [Related]
9. PKMYT1 induced by YAP/TEAD1 gives rise to the progression and worse prognosis of bladder cancer.
Wang M; Zhang C; Ying Y; Hua M; Meng F; Wang Z; Liu A; Zeng S; Zhang Z; Xu C
Mol Carcinog; 2024 Jan; 63(1):160-172. PubMed ID: 37787394
[TBL] [Abstract][Full Text] [Related]
10. Silencing TTK expression inhibits the proliferation and progression of prostate cancer.
Chen S; Wang J; Wang L; Peng H; Xiao L; Li C; Lin D; Yang K
Exp Cell Res; 2019 Dec; 385(1):111669. PubMed ID: 31605696
[TBL] [Abstract][Full Text] [Related]
11. [Effect of downregulation of prostate cancer antigen-1 expression on malignant biological behavior of prostate cancer LNCaP cells].
Liu BQ; Wang YK; Wu YD; Wei JX; Li X
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):828-32. PubMed ID: 24447480
[TBL] [Abstract][Full Text] [Related]
12. PKMYT1 promoted the growth and motility of hepatocellular carcinoma cells by activating beta-catenin/TCF signaling.
Liu L; Wu J; Wang S; Luo X; Du Y; Huang D; Gu D; Zhang F
Exp Cell Res; 2017 Sep; 358(2):209-216. PubMed ID: 28648520
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-107 inhibits proliferation of prostate cancer cells by targeting cyclin E1.
Zhang X; Jin K; Luo JD; Liu B; Xie LP
Neoplasma; 2019 Sep; 66(5):704-716. PubMed ID: 31129966
[TBL] [Abstract][Full Text] [Related]
14. Transcription factor TEAD4 facilitates glycolysis and proliferation of gastric cancer cells by activating PKMYT1.
Zhan L; Wu W; Yang Q; Shen H; Liu L; Kang R
Mol Cell Probes; 2023 Dec; 72():101932. PubMed ID: 37729973
[TBL] [Abstract][Full Text] [Related]
15. Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
Szychowski J; Papp R; Dietrich E; Liu B; Vallée F; Leclaire ME; Fourtounis J; Martino G; Perryman AL; Pau V; Yin SY; Mader P; Roulston A; Truchon JF; Marshall CG; Diallo M; Duffy NM; Stocco R; Godbout C; Bonneau-Fortin A; Kryczka R; Bhaskaran V; Mao D; Orlicky S; Beaulieu P; Turcotte P; Kurinov I; Sicheri F; Mamane Y; Gallant M; Black WC
J Med Chem; 2022 Aug; 65(15):10251-10284. PubMed ID: 35880755
[TBL] [Abstract][Full Text] [Related]
16. Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis.
Liu Y; Qi J; Dou Z; Hu J; Lu L; Dai H; Wang H; Yang W
Cell Prolif; 2020 Feb; 53(2):e12741. PubMed ID: 31837068
[TBL] [Abstract][Full Text] [Related]
17. Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases.
Schmidt M; Rohe A; Platzer C; Najjar A; Erdmann F; Sippl W
Molecules; 2017 Nov; 22(12):. PubMed ID: 29168755
[TBL] [Abstract][Full Text] [Related]
18. Compound K is a potential clinical anticancer agent in prostate cancer by arresting cell cycle.
Liu M; Zhang Y; Zhang A; Deng Y; Gao X; Wang J; Wang Y; Wang S; Liu J; Chen S; Yao W; Liu X
Phytomedicine; 2023 Jan; 109():154584. PubMed ID: 36610114
[TBL] [Abstract][Full Text] [Related]
19. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
20. PKMYT1, exacerbating the progression of clear cell renal cell carcinoma, is implied as a biomarker for the diagnosis and prognosis.
Chen J; Hua X; Chen H; Qiu X; Xiao H; Ge S; Liang C; Zhou Q
Aging (Albany NY); 2021 Dec; 13(24):25778-25798. PubMed ID: 34959223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
